![](https://www.healio.com/~/media/slack-news/fm_im/misc/infographics/2024/01-january/semaglutide_stock_1200x630.jpg)
GLP-1 receptor agonist prescriptions for obesity have risen in those without diabetes
Semaglutide was the highest newly prescribed GLP-1 receptor agonist in 2023. The proportion of new users without FDA-approved indications rose from 0.21% to 0.37% from 2019 to 2023. New prescriptions of GLP-1 receptor agonists for the treatment of obesity …